AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10771931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemic children
Number of subjects: 233
Study 10771931 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalassemic children with hemoglobin levels < 8 gm/dl
Number of subjects: 233
Study 10771931 — intervention group
Group type: COMPARATOR
Intervention: Non-thalassemic siblings
Number of subjects: 233
Study 7875187 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER) 10 mg immediate release and 60 mg slow release
Number of subjects: 8
Study 7875187 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER)
Number of subjects: 8
Study 7875187 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate extended-release (ISDN-ER) after 14 days of treatment
Number of subjects: 8
Study 7875187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic measurements of ISDN
Number of subjects: 8
Study 7875187 — intervention group
Group type: EXPERIMENTAL
Intervention: ISDN before drug after 14 days of treatment
Number of subjects: 8
Study 3359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment only for reflux grade III or less
Number of subjects: 95
Study 3359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus antibiotic treatment for reflux grade IV
Number of subjects: 95
Study 3359122 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic treatment alone for reflux grade IV
Number of subjects: 95
Study 3359122 — intervention group
Group type: EXPERIMENTAL
Intervention: Reimplantation for reflux grade V
Number of subjects: 95
Study 29426348 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (semi-individualized acupuncture points)
Number of subjects: 0
Study 29426348 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (minimal acupuncture on non-acupuncture points)
Number of subjects: 0
Study 27255763 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Number of subjects: 34
Study 25982108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing GDMT plus Baroreflex Activation Therapy (BAT) for 6 months
Number of subjects: 146
Study 25982108 — intervention group
Group type: COMPARATOR
Intervention: Ongoing GDMT alone for 6 months
Number of subjects: 146
Study 23676933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) suspension
Number of subjects: 118
Study 23676933 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ) tablets
Number of subjects: 118
Study 20233196 — intervention group
Group type: EXPERIMENTAL
Intervention: S-0139 (15 μg kg-1 min-1)
Number of subjects: 0
Study 20233196 — intervention group
Group type: EXPERIMENTAL
Intervention: S-0139 (15.7 μg kg-1 min-1) in delayed administration study
Number of subjects: 0
Study 20233196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20233196 — intervention group
Group type: EXPERIMENTAL
Intervention: S-0139 (2.5 μg kg-1 min-1)
Number of subjects: 0
Study 20233196 — intervention group
Group type: EXPERIMENTAL
Intervention: S-0139 (6.67 μg kg-1 min-1)
Number of subjects: 0
Study 20233196 — intervention group
Group type: EXPERIMENTAL
Intervention: S-0139 (0.08-13.33 μg kg-1 min-1) in pilot study
Number of subjects: 0
Study 18184294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol
Number of subjects: 30
Study 18184294 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 30
Study 16496208 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI (two inseminations 18-24 and 36-48 hours post hCG injection)
Number of subjects: 1270
Study 16496208 — intervention group
Group type: COMPARATOR
Intervention: Single IUI (one insemination 34 hours post hCG administration)
Number of subjects: 1270
Study 16496208 — intervention group
Group type: COMPARATOR
Intervention: Single IUI in male factor infertility (M(1))
Number of subjects: 1270
Study 16496208 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI in male factor infertility (M(2))
Number of subjects: 1270
Study 16496208 — intervention group
Group type: COMPARATOR
Intervention: Single IUI in idiopathic infertility (I(1))
Number of subjects: 1270
Study 16496208 — intervention group
Group type: EXPERIMENTAL
Intervention: Double IUI in idiopathic infertility (I(2))
Number of subjects: 1270
Study 12634583 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 242
Study 12634583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 10073156 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests (FOBT)
Number of subjects: 0
Study 10073156 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy, colonoscopy, double-contrast barium enema
Number of subjects: 0
Study 10073156 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot colorectal cancer screening programmes
Number of subjects: 0
Study 10073156 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal occult blood testing outside a population screening programme
Number of subjects: 0
Study 10163712 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 1695783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical or surgical treatment for BPH
Number of subjects: 0
Study 1695783 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic assessment of symptomatology and baseline minimal urodynamic evaluation
Number of subjects: 0
Study 324177 — intervention group
Group type: EXPERIMENTAL
Intervention: Live dysentery Sonne vaccine (3 to 25 milliard live microbial cells, single and triple immunization schemes)
Number of subjects: 0
Study 324177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 324177 — intervention group
Group type: EXPERIMENTAL
Intervention: Live dysentery Sonne vaccine
Number of subjects: 0
Study 31438413 — intervention group
Group type: EXPERIMENTAL
Intervention: Connected system for telerehabilitation
Number of subjects: 15
Study 28712987 — intervention group
Group type: EXPERIMENTAL
Intervention: TAILORED intervention (intensive nurse-directed discussion of end-of-life decision control preferences)
Number of subjects: 166
Study 28712987 — intervention group
Group type: COMPARATOR
Intervention: CONTROL intervention (discussion of nutrition)
Number of subjects: 166
Study 25557395 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Regulation Group Therapy (ERGT)
Number of subjects: 61
Study 25557395 — intervention group
Group type: COMPARATOR
Intervention: Ongoing outpatient therapy
Number of subjects: 61
Study 24781217 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal non-invasive positive pressure ventilation (NIV)
Number of subjects: 201
Study 24781217 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 201
Study 21924382 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear mixed model (conditional)
Number of subjects: 0
Study 21924382 — intervention group
Group type: EXPERIMENTAL
Intervention: Marginal proportional hazards model with robust standard errors
Number of subjects: 0
Study 21924382 — intervention group
Group type: COMPARATOR
Intervention: Clustered logrank test
Number of subjects: 0
Study 21924382 — intervention group
Group type: COMPARATOR
Intervention: Clustered permutation test (non-parametric)
Number of subjects: 0
Study 19211596 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis (EFA) on motor and non-motor symptoms in PD
Number of subjects: 397
Study 19211596 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis based on EFA findings
Number of subjects: 397
Study 19211596 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple regression analyses on resulting factors
Number of subjects: 397
Study 17972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB) prime
Number of subjects: 100
Study 17972451 — intervention group
Group type: COMPARATOR
Intervention: Packed red blood cell (PRBC) prime
Number of subjects: 100
Study 17972451 — intervention group
Group type: EXPERIMENTAL
Intervention: < 5 kg FWB prime
Number of subjects: 100
Study 17972451 — intervention group
Group type: COMPARATOR
Intervention: < 5 kg PRBC prime
Number of subjects: 100
Study 17972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB)
Number of subjects: 100
Study 17972451 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-bypass ultrafiltration (PBUF)
Number of subjects: 100
Study 15151729 — intervention group
Group type: EXPERIMENTAL
Intervention: Office hystroscopy (Group II)
Number of subjects: 421
Study 12378744 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0
Study 12378744 — intervention group
Group type: COMPARATOR
Intervention: Pamidronic acid
Number of subjects: 0
Study 9824184 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg loading dose followed by 30 mg every 6 hours for a maximum of 24 hours)
Number of subjects: 88
Study 9824184 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate (initial 6 g intravenous bolus followed by continuous infusion therapy 2 to 6 g/hr)
Number of subjects: 88
Study 9824184 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study 7926139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg injected locally in the ectopic gestational sac and 1 mg/kg by IM administration 48 hours later
Number of subjects: 48
Study 7926139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg locally
Number of subjects: 48
Study 7926139 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg locally
Number of subjects: 48
Study 7926139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg by IM administration
Number of subjects: 48
Study 3617193 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplement of iron, thiamine, riboflavin, and vitamin C for 3 months
Number of subjects: 190
Study 3617193 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 190
Study 28842994 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative- and adjuvant-free trivalent split vaccine
Number of subjects: 0
Study 28842994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27871520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 120
Study 27871520 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 120
Study 27871520 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 120
Study 25192259 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5mg letrozole
Number of subjects: 88
Study 25192259 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mg letrozole
Number of subjects: 88
Study 25192259 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5mg letrozole
Number of subjects: 88
Study 25192259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 22638811 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 18
Study 22638811 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 40 mg
Number of subjects: 18
Study 22638811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22638811 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (both doses)
Number of subjects: 18
Study 22638811 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 18
Study 20919666 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4
Study 20919666 — intervention group
Group type: COMPARATOR
Intervention: Carotid artery endarterectomy (CEA)
Number of subjects: 4
Study 18665373 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 200
Study 18665373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 19954476 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with polymyxin B-immobilized fiber (DHP-PMX)
Number of subjects: 12
Study 15820077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphatic chemotherapy (LC) - subcutaneously injected with 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin) around the primary tumor.
Number of subjects: 60
Study 15820077 — intervention group
Group type: COMPARATOR
Intervention: Intravenous chemotherapy (VC) - intravenously injected with an equal dose of aqueous carboplatin.
Number of subjects: 60
Study 11422760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead chelation therapy
Number of subjects: 30
Study 11422760 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 30
Study 9205819 — intervention group
Group type: EXPERIMENTAL
Intervention: MP suleptanate (250 mg intramuscular injection)
Number of subjects: 20
Study 9205819 — intervention group
Group type: COMPARATOR
Intervention: MP succinate (250 mg intramuscular injection)
Number of subjects: 20
Study 9205819 — intervention group
Group type: EXPERIMENTAL
Intervention: MP suleptanate
Number of subjects: 20
Study 9205819 — intervention group
Group type: COMPARATOR
Intervention: MP succinate
Number of subjects: 20
Study 7954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.03 mg.kg-1 and infusion rate of 0.5 micrograms.kg-1.min-1
Number of subjects: 30
Study 7954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.06 mg.kg-1 and infusion rate of 1.0 micrograms.kg-1.min-1
Number of subjects: 30
Study 7954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.1 mg.kg-1 and infusion rate of 1.5 micrograms.kg-1.min-1
Number of subjects: 30
Study 7954994 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine given in increments of 2.0 mg iv prn for analgesia
Number of subjects: 30
Study 7954994 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study 3475886 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBY)
Number of subjects: 57
Study 3475886 — intervention group
Group type: COMPARATOR
Intervention: Gastroplasty (GPL)
Number of subjects: 57
Study 31308209 — intervention group
Group type: EXPERIMENTAL
Intervention: Giant cell arteritis (GCA) patients
Number of subjects: 767
Study 31308209 — intervention group
Group type: COMPARATOR
Intervention: Matched population controls
Number of subjects: 767
Study 30838110 — intervention group
Group type: EXPERIMENTAL
Intervention: 10G drain
Number of subjects: 105
Study 30838110 — intervention group
Group type: EXPERIMENTAL
Intervention: 12G drain
Number of subjects: 105
Study 30838110 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 105
Study 30838110 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study 28606095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg once weekly
Number of subjects: 0
Study 26724628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EVD and Ommaya reservoir with urokinase (20,000 IU/dose)
Number of subjects: 60
Study 26724628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EVD and Ommaya reservoir
Number of subjects: 60
Study 26724628 — intervention group
Group type: COMPARATOR
Intervention: Conventional EVD alone
Number of subjects: 60
Study 24335723 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge (Gelfoam)
Number of subjects: 82
Study 24335723 — intervention group
Group type: COMPARATOR
Intervention: Control group (no absorbable gelatin sponge)
Number of subjects: 82
Study 22344063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and aerobic training
Number of subjects: 73
Study 22344063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and resistance training
Number of subjects: 73
Study 22344063 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 73
Study 19294387 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 50 mg daily (arm A)
Number of subjects: 194
Study 19294387 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 150 mg daily (arm B)
Number of subjects: 194
Study 19294387 — intervention group
Group type: EXPERIMENTAL
Intervention: CI-1033 450 mg/day x 14 days every 21 days (arm C)
Number of subjects: 194
Study 17709456 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient-fortified beverage
Number of subjects: 1125
Study 17709456 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified beverage (Control)
Number of subjects: 1125
Study 15563362 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole administered orally every 24 h for 29 days
Number of subjects: 0
Study 12035596 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% administered in monotherapy (2 times a day)
Number of subjects: 26
Study 12035596 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% administered in adjunctive therapy (3 times a day)
Number of subjects: 26
Study 12035596 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide in combination with other therapies
Number of subjects: 26
Study 12035596 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 26
Study 9560041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematil‐LCP
Number of subjects: 20
Study 9560041 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematil
Number of subjects: 20
Study 9560041 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 20
Study 7813597 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune intervention protocols avoiding immunosuppressants
Number of subjects: 0
Study 7813597 — intervention group
Group type: EXPERIMENTAL
Intervention: Supporting the defence of islet cells against inflammatory attack
Number of subjects: 0
Study 7813597 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing exposure to putative diabetogenic dietary factors during infancy
Number of subjects: 0
Study 3310629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g three times a day one‐half hour before meals for four weeks)
Number of subjects: 151
Study 3310629 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 g three times a day one‐half hour before meals for four weeks)
Number of subjects: 151
Study 3310629 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 151
Study 3310629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 29497286 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat insoles
Number of subjects: 100
Study 29497286 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured insoles
Number of subjects: 100
Study 29497286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no insoles)
Number of subjects: 100
Study 27639557 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Act and Feel Indonesia (GAF-ID) - Internet-based behavioral activation treatment with support from lay counselors.
Number of subjects: 312
Study 27639557 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE) - online-delivered minimal psychoeducation without any support.
Number of subjects: 312
Study 25016780 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP serum concentrations in patients with adenomas located proximally (8.674 +/- 9.19 microg/ml)
Number of subjects: 60
Study 25016780 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha concentration in patients with adenomas (24.51 +/- 13.50 pg/ml)
Number of subjects: 60
Study 25016780 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 serum level in patients with colon adenomas (19.80 +/- 7.44 pg/ml)
Number of subjects: 60
Study 23786283 — intervention group
Group type: EXPERIMENTAL
Intervention: Current exposure to dampness
Number of subjects: 46051
Study 23786283 — intervention group
Group type: EXPERIMENTAL
Intervention: Damp homes
Number of subjects: 46051
Study 20002646 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)‐PDT
Number of subjects: 14
Study 18824995 — intervention group
Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 3 days post-injury
Number of subjects: 13
Study 18824995 — intervention group
Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 15 days post-injury
Number of subjects: 13
Study 18824995 — intervention group
Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 30 days post-injury
Number of subjects: 13
Study 18824995 — intervention group
Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 45 days post-injury (for those with second concussive injury)
Number of subjects: 13
Study 18824995 — intervention group
Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 15 days post-second injury
Number of subjects: 13
Study 17119800 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist immobilization (neutral-position wrist splint) for two weeks
Number of subjects: 52
Study 17119800 — intervention group
Group type: COMPARATOR
Intervention: No wrist immobilization
Number of subjects: 52
Study 12037755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical management (group 1)
Number of subjects: 82
Study 12037755 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (group 2)
Number of subjects: 82
Study 12037755 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 82
Study 11188564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal lidocaine
Number of subjects: 50
Study 11188564 — intervention group
Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 50
Study 7559897 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur); n = 23
Number of subjects: 40
Study 7559897 — intervention group
Group type: COMPARATOR
Intervention: Long acting GnRH analog (Decapeptyl Depot); n = 17
Number of subjects: 40
Study 1967134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who wished to die at home (34 patients, 58%)
Number of subjects: 98
Study 1967134 — intervention group
Group type: COMPARATOR
Intervention: Patients who died in hospital (32 patients)
Number of subjects: 98
Study 1967134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with more favorable circumstances (41 patients, 67%)
Number of subjects: 98
Study 1967134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who preferred to die in hospital (10 patients, 16%)
Number of subjects: 98
Study 1967134 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who preferred to die in hospice (9 patients, 15%)
Number of subjects: 98